Protecting against ischemia-reperfusion injury: Antiplatelet drugs, statins, and their potential interactions

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 76-82

  Ye, Yumei ^a   Perez Polo, Jose R ^a   Birnbaum, Yochai ^a,b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Antiplatelet agents; Aspirin; Cilostazol; Dipyridamole; Infarct size; Ischemia reperfusion injury; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CILOSTAZOL; CYCLOOXYGENASE 2; DIPYRIDAMOLE; ECTO 5' NUCLEOTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIMVASTATIN; TETRAZOLE DERIVATIVE;

ARTICLE; DRUG EFFECT; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; ISCHEMIA REPERFUSION INJURY; REPERFUSION INJURY; BIOLOGICAL MODEL; DRUG INTERACTION; HEART INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ASPIRIN; DIPYRIDAMOLE; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, CARDIOVASCULAR; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PLATELET AGGREGATION INHIBITORS; SIMVASTATIN; TETRAZOLES;

EID: 78149267940     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05725.x     Document Type: Article

References (39)

1. Antman, E.M. et al. 2004.ACC/AHAguidelines for themanagement of patientswith ST-elevationmyocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J. Am Coll. Cardiol. 44: E1-E211.
2. Kushner, F.G. et al. 2009. 2009 focused updates: ACC/AHA guidelines for themanagement of patientswith ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am Coll. Cardiol. 54: 2205-2241.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1988. Lancet 2: 349-360.
4. Birnbaum, Y. et al. 2003. Reduction of infarct size by shorttermpretreatmentwith atorvastatin. Cardiovasc.Drugs Ther. 17: 25-30.
5. Kureishi, Y. et al. 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6: 1004-1010.
6. Merla, R. et al. 2007. The central role of adenosine in statininduced ERK1/2, Akt, and eNOS phosphorylation. Am J. Physiol. Heart Circ. Physiol. 293: H1918-H1928.
7. Birnbaum, Y. et al. 2006. Mechanism of myocardial protection by atorvastatin: 5'-nucleotidase is upstream of eNOS activation. Circ. Res. 99: E26.
8. Dubey, R.K., D.G. Gillespie & E.K. Jackson. 2002. A(2B) adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension 39: 530-535.
9. Sexl, V. et al. 1997. Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells. J. Biol. Chem. 272: 5792- 5799.
10. Fang, Y. & M.E. Olah. 2007. Cyclic AMP-dependent, protein kinase A-independent activation of extracellular signalregulated kinase 1/2 following adenosine receptor stimulation in human umbilical vein endothelial cells: role of exchange protein activated by cAMP 1 (Epac1). J. Pharmacol. Exp. Ther. 322: 1189-1200.
11. Harris, M.B. et al. 2004. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J. Physiol. Heart Circ. Physiol. 287: H560-H566.
12. Manickavasagam, S. et al. 2007. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc. Drugs Ther. 21: 321-330.
13. Atar, S. et al. 2006. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J. Physiol. Heart Circ. Physiol. 290: H1960-H1968.
14. Birnbaum, Y. et al. 2005. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemiareperfusion injury. Cardiovasc Res. 65: 345-355.
15. Birnbaum, Y. et al. 2007. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J. Physiol. Heart Circ. Physiol. 292: H2891-H2897.
16. Ye, Y. et al. 2007. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and lowdose atorvastatin combination. Am J. Physiol. Heart Circ. Physiol. 293: H813-H818.
17. Range, S.P. et al. 2000. Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smoothmuscle cells. Eur. Respir J. 15: 751-756.
18. Shinmura, K. et al. 2003. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J. Am. Coll. Cardiol. 41: 1183-1194.
19. Serhan, C.N. 2005. Lipoxins and aspirin-triggered 15-epilipoxins are the first lipid mediators of endogenous antiinflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids. 73: 141-162.
20. Birnbaum, Y. et al. 2007. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 83: 89-98.
21. Schaper,W. 2005. Dipyridamole, an underestimated vascular protective drug. Cardiovasc. Drugs Ther. 19: 357-363.
22. Taniguchi, M. et al. 2004. Dipyridamole protects the liver against warm ischemia and reperfusion injury. J. Am Coll. Surg. 198: 758-769.
23. Suzuki, K. et al. 1998. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J. Cardiovasc. Pharmacol. 31: 1-9.
24. Ye, Y. et al. 2010. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc. Drugs. Ther. [Epub ahead of print].
25. Kambayashi, J. et al. 2003. Cilostazol as a unique antithrombotic agent. Curr. Pharm. Des. 9: 2289-2302.
26. Hashimoto, A. et al. 2006. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase Aand phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189: 350-357.
27. Liu, Y. et al. 2000. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol. 36: 351-360.
28. Lotfi, A. et al. 2008. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients: a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.Am. Heart J. 155: 954-958.
29. Mullangi, R. & N.R. Srinivas. 2009. Clopidogrel: review of bioanalytical methods, pharmacokinetics/ pharmacodynamics, and update on recent trends in drugdrug interaction studies. Biomed. Chromatogr. 23: 26-41.
30. Scalia, R. et al. 2001. Simvastatin exerts both antiinflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103: 2598-2603.
31. Ye, Y. et al. 2008. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am. J. Physiol. Heart Circ. Physiol. 295: H343-H351.
32. Smith, A.R. & T.M. Hagen. 2003. Vascular endothelial dysfunction in aging: loss of Akt-dependent endothelial nitric oxide synthase phosphorylation and partial restoration by (R)-alpha-lipoic acid. Biochem. Soc. Trans. 31: 1447- 1449.
33. Stockklauser-Farber, K. et al. 2000. Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim. Biophys. Acta. 1535: 10-20.
34. Ratajczak, P. et al. 2003. Caveolin-1 and -3 dissociations from caveolae to cytosol in the heart during aging and after myocardial infarction in rat. Cardiovasc. Res. 57: 358-369.
35. Sacco, R.L. et al. 2008. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359: 1238-1251.
36. Liao, J.K. 2007. Secondary prevention of stroke and transient ischemic attack: ismore platelet inhibition the answer? Circulation 115: 1615-1621.
37. Han, Y. et al. 2009. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am. Heart J. 157: 733-739.
38. Singh, I. et al. 2009. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br. J. Clin. Pharmacol. 68: 4-13.
39. Angiolillo, D.J. et al. 2008. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29: 2202-2211